Age-standardized cardiovascular mortality fell from 340.2 to 258.4 deaths per 100,000 globally between 2000 and 2023, analyzed across 4,896 country-year observations using two-way fixed-effects panel regression. Elevated systolic blood pressure showed the strongest independent association with CVD mortality (β = 1.129), accounting for 70.91% of the total decline. High LDL cholesterol (β = 0.622), smoking (β = 0.452), and fasting glucose (β = 0.410) independently contributed, while high BMI showed no direct mortality association (β = 0.049, P = 0.421) — with 99.2% of its impact mediated through downstream metabolic pathways including blood pressure, glucose, and lipids. Critically, progress stalled post-2019, with annual mortality declines collapsing from −1.31% to −0.03%.
This large-scale ecological analysis, not yet peer-reviewed, offers one of the most granular decompositions of CVD risk pathways at global scale. The finding that BMI operates almost entirely through metabolic intermediaries has significant clinical implications: it reframes obesity as an upstream systems driver rather than a direct mortality risk, suggesting that treating its downstream consequences — hypertension, dyslipidemia, hyperglycemia — may yield faster mortality reductions than weight loss alone. The post-2019 deceleration warrants urgent attention; pandemic disruptions to healthcare access likely contributed but may not fully explain it. Limitations include ecological design precluding individual-level causal inference, potential GBD data quality variation across low-income nations, and residual confounding. Nonetheless, the prioritization of universal blood pressure control as the single highest-leverage intervention is a confirmatory and policy-relevant conclusion.
